trending Market Intelligence /marketintelligence/en/news-insights/trending/Zjalx8yICwHFtS4VHDB3mQ2 content esgSubNav
In This List

KemPharm's acute pain drug gains FDA fast-track designation

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


KemPharm's acute pain drug gains FDA fast-track designation

The U.S. FDA granted fast-track designation to KemPharm Inc.'s co-lead product candidate, KP201/IR, for the treatment of acute pain.

The company plans to start human clinical trials of the product in the first half of 2017.

KemPharm remains on target for the potential submission of a new drug application for KP201/IR in 2018, President and CEO Travis Mickle said in a statement.